The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Health-related quality of life (HRQoL) results for adjuvant alectinib vs chemotherapy in patients with resected ALK+ non-small cell lung cancer (NSCLC): Data from ALINA.
 
Makoto Nishio
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Eisai; Janssen; Lilly; Merck; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Yi-Long Wu
Honoraria - AstraZeneca; BeiGene Beijing; Boehringer Ingelheim; Bristol-Myers Squibb/China; Hengrui Pharmaceutical; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche; Takeda
Research Funding - BMS (Inst); Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)
 
Fabrice Barlesi
Consulting or Advisory Role - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai Europe (Inst); Lilly (Inst); Merck Serono (Inst); Mirati Therapeutics (Inst); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Ipsen (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Jin Seok Ahn
Honoraria - Amgen; AstraZeneca; Bayer; BC World Pharmaceutical; Boehringer Ingelheim; Boryung; Kyowa Kirin; Lilly; Menarini; Nokwon Medical; Novartis; Pfizer; Roche; Samyang; Takeda; Yuhan
Consulting or Advisory Role - Daiichi Sankyo Korea; Guardant Health; ImmuneOncia; Pharmbio Korea; Roche; Therapex; Yuhan
 
Dae Ho Lee
Honoraria - Abbvie; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; ChongKeunDang Healthcare; Janssen; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech; ST Cube; Takeda; Yuhan
Consulting or Advisory Role - ABION; ST Cube
 
Jong-Seok Lee
No Relationships to Disclose
 
Wenzhao Zhong
No Relationships to Disclose
 
Hidehito Horinouchi
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; Merck Serono; MSD Oncology; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Novocure; Seagen; Yuhan
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BMKK (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Maximilian Hochmair
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Lilly; Roche; Takeda
Speakers' Bureau - Lilly; MSD Oncology; Novartis; Roche
 
Hiroshi Tanaka
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Lilly; Merck KGaA; MSD; Nihonkayaku; Novartis; Ono Pharmaceutical; Pfizer; Sun Pharma; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; MSD Oncology
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Maciej Glogowski
Honoraria - AstraZeneca; Roche
Consulting or Advisory Role - AstraZeneca
 
Achim Rittmeyer
Consulting or Advisory Role - AbbVie; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; MSD; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - Bristol-Myers Squibb; Lilly; MSD; Novartis; Roche/Genentech
 
Mary J. Fidler
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb/Pfizer; Daiichi Sankyo/Astra Zeneca; G1 Therapeutics; Genentech; Gilead Sciences; Janssen; Jazz Pharmaceuticals; Lilly; Novocure; Oncohost; Proventus Group; Regeneron; Sanofi; Takeda; Tempus
Speakers' Bureau - EMD Serono
Research Funding - alkermes (Inst); AstraZeneca (Inst); Gilead Sciences (Inst); Jounce Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer/EMD Serono
 
Anna Wrona
Consulting or Advisory Role - Takeda
Speakers' Bureau - Bristol-Myers Squibb; F, Hoffmann-La Roche Ltd; Pfizer; Takeda
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer; Roche; Takeda
 
Carla Mamolo
Employment - Genentech; Pfizer
Stock and Other Ownership Interests - Genentech; Pfizer
 
Andrés Cardona
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Thorsten Ruf
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Vlatka Smoljanovic
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Benjamin J. Solomon
Honoraria - Amgen (Inst); AstraZeneca; Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche/Genentech
Consulting or Advisory Role - Amgen; AstraZeneca (Inst); BeiGene; Bristol-Myers Squibb (Inst); GlaxoSmithKline; GlaxoSmithKline (Inst); Janssen (Inst); Lilly; Merck Sharp & Dohme; Pfizer (Inst); Roche/Genentech (Inst); Takeda
Research Funding - Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate